Unknown

Dataset Information

0

Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways.


ABSTRACT: BACKGROUND AND PURPOSE:The intraocular pressure (IOP)-lowering and side effects in response to different prostaglandin F2? analogues can be variable, but, the underlying basis for this difference remains unknown. This study investigated the differential changes of cellular proteins relevant to IOP-lowering effects of latanoprost and bimatoprost. METHODS:The human T lymphoblast (MOLT-3) cell line and immortalized human trabecular meshwork (iHTM) cells were studied by quantitative PCR and by immunofluorescence after treatment with either latanoprost or bimatoprost. New Zealand white rabbit eyes were treated topically with each agent and, following euthanasia, anterior segment tissues were studied with immunostaining. RESULTS:In cultured MOLT-3 cells, mRNA expression of both c-fos and matrix metalloproteinase 9 increased significantly in response to each agent. In addition, there was little change in tissue inhibitor of metalloproteinase (TIMP)-3 mRNA, but a significant decrease in TIMP-4. Fibronectin mRNA in MOLT-3 cells was down-regulated with bimatoprost, but was up-regulated with latanoprost. Immunofluorescence analysis of iHTM cells showed that intracellular fibronectin was significantly decreased by bimatoprost, but was increased by latanoprost. Both latanoprost and bimatoprost increased mRNA expression of NF-?B p65 and decreased that of I?B?. Aquaporin-1 mRNA expression was significantly down-regulated by bimatoprost. Immunostaining also revealed a significant decrease of aquaporin-1 in the ciliary epithelium of New Zealand white rabbits after bimatoprost treatment. CONCLUSIONS:Similarities in protein expression produced by latanoprost and bimatoprost in vitro may be relevant to the mechanism for their IOP-lowering effects in vivo. Differences in fibronectin expression and in aquaporin-1 expression in response to each agent may contribute to variability in the IOP-lowering efficacy in some studies.

SUBMITTER: Li X 

PROVIDER: S-EPMC4807090 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC3971936 | BioStudies
2010-01-01 | S-EPMC2793510 | BioStudies
2019-01-01 | S-EPMC6451067 | BioStudies
2017-01-01 | S-EPMC5519176 | BioStudies
2016-01-01 | S-EPMC5085282 | BioStudies
1000-01-01 | S-EPMC4228301 | BioStudies
2010-01-01 | S-EPMC3000769 | BioStudies
2016-01-01 | S-EPMC5025541 | BioStudies
2018-01-01 | S-EPMC6078293 | BioStudies
2019-01-01 | S-EPMC6451111 | BioStudies